Medicinal – Page 83

Discovery of novel targets for important human and plant fungal pathogens via an automated computational pipeline HitList

mycolabadmin

Researchers created a computer program called HitList that searches fungal DNA to find new targets for antifungal medications. The program identified 16 promising protein targets that could be attacked by new antifungal drugs, including 8 completely new targets never before considered. This discovery could help develop new antifungal treatments to fight drug-resistant fungal infections in both humans and crops.

A 3D Fusarium keratitis model reveals isolate-specific adhesion and invasion properties in the Fusarium solani species complex

mycolabadmin

Researchers studied three species of Fusarium fungus that cause serious eye infections. They found that one species (F. keratoplasticum) is much more dangerous than the others, invading deeper into the eye and causing more damage. Using a new 3D model that mimics the structure of the human cornea, they discovered that Fusarium fungi penetrate much deeper than other fungal pathogens, which helps explain why eye infections from these fungi are so difficult to treat and why patients often lose their vision.

An Optimized In-House Protocol for Cryptococcus neoformans DNA Extraction from Whole Blood: Comparison of Lysis Buffer and Ox-Bile Methods

mycolabadmin

Researchers developed a simple, low-cost method to extract DNA from Cryptococcus neoformans fungal cells found in blood samples. The new method uses a homemade salt buffer solution instead of expensive commercial kits, making it accessible to laboratories in developing countries. Testing showed this method works better than an alternative ox-bile method, detecting very small numbers of fungal cells. This breakthrough could help doctors more quickly diagnose a serious fungal infection called cryptococcal meningitis in resource-limited settings.

Past, present and future of antifungals: Advancements in mechanisms of action and resistance

mycolabadmin

Fungal infections are a growing global health threat, especially for people with weakened immune systems, causing millions of deaths annually. Currently available antifungal drugs are limited and increasingly face resistance, making them less effective over time. This special collection of research papers explores new approaches to treating fungal infections, including novel drugs, combination therapies, and alternative treatments to overcome resistance. Scientists and doctors hope these advances will help save more lives by providing better options for treating serious fungal diseases.

Haplotype-resolved genomes of Phlebopus portentosus reveal nuclear differentiation, TE-mediated variation, and saprotrophic potential

mycolabadmin

Scientists sequenced the complete genomes of two compatible strains of the king bolete mushroom (Phlebopus portentosus), an important edible and medicinal species. The study found that mobile DNA elements called transposons play a major role in creating genetic differences between the two fungal nuclei and in generating the diversity of compounds that give mushrooms their health benefits. The research shows this mushroom can both partner with trees and break down organic material on its own, making it uniquely adaptable.

Influenza-related invasive pulmonary aspergillosis in an infectious disease ward at a pulmonary referral center in Iran

mycolabadmin

This study examined patients hospitalized with influenza who developed a serious fungal infection caused by Aspergillus fungus. Among 109 influenza patients, about 9% developed this fungal complication which significantly increased their risk of death and required longer hospital stays. Patients with existing lung diseases were at higher risk, and those with the fungal infection also had more bacterial superinfections. The findings highlight the importance of recognizing and treating this serious fungal complication in hospitalized influenza patients.

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

mycolabadmin

This study analyzed the chemical composition of ‘magic mushrooms’ (Psilocybe) at different growth stages—liquid cultures, grain cultures, and mature fruiting bodies. Using advanced laboratory techniques, researchers found that fruiting bodies contain the highest levels of psilocybin (the psychoactive compound), while mycelium contains unique beneficial compounds like alpha-glycerylphosphorylcholine that may have therapeutic value without strong psychedelic effects. The findings suggest that Psilocybe mycelium could be developed as a non-intoxicating health supplement with potential therapeutic applications.

Insights into microbiome-triterpenoid correlation in Poria cocos via comparative analysis of sclerotial and soil microenvironments

mycolabadmin

Researchers discovered that the medicinal fungus Poria cocos creates its own specialized microbial environment in its underground structure that is closely linked to the production of pachymic acid, a compound with anti-cancer and immune-boosting properties. By comparing the microbes living in the fungus versus surrounding soil, they found specific beneficial bacteria and fungi that thrive in the fungus but are rare in soil. This discovery could help improve cultivation techniques to produce higher quality medicinal fungi with more therapeutic compounds.

Inonotus hispidus Protects against Hyperlipidemia by Inhibiting Oxidative Stress and Inflammation through Nrf2/NF-κB Signaling in High Fat Diet Fed Mice

mycolabadmin

Inonotus hispidus is an edible mushroom that may help treat obesity and high cholesterol by reducing fat levels and inflammation in the body. In mice fed a high-fat diet, the mushroom improved cholesterol profiles, reduced liver damage, and promoted beneficial gut bacteria. The beneficial effects appear to work through activating the body’s natural antioxidant defenses and reducing inflammation-causing proteins.

Butyrate ameliorates quinolinic acid–induced cognitive decline in obesity models

mycolabadmin

This research shows that overweight and obese individuals have higher levels of a toxic compound called quinolinic acid in their bodies, which is linked to memory problems and brain shrinkage. The good news is that butyrate, a substance naturally produced by gut bacteria when we eat fiber, can protect against these harmful effects. Butyrate works by activating genes that produce brain-derived neurotrophic factor (BDNF), a protein essential for brain health and memory formation. The study suggests that increasing butyrate through diet or supplements could help prevent cognitive decline associated with obesity.

Research Topic: Medicinal